Evaluate Therapeutic Equivalence and Safety of Two Clindamycin Phosphate and Benzoyl Peroxide Gels in Acne Vulgaris

Watson Pharmaceuticals

Status and phase: Completed; Phase 3

Conditions: Acne Vulgaris

Treatments: Drug: Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%; Drug: Clindamycin Phosphate / Benzoyl Peroxide Gel; Drug: Placebo (Vehicle Gel)

Study type: Interventional

Funder types: Industry

Identifiers

NCT01788384

12-1001

Details and patient eligibility

About

Acanya (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% gel marketed by Valeant Pharmaceuticals, North America, is a safe and effective topical therapy used for the treatment of acne vulgaris.

Full description

Watson Laboratories, Inc. has developed a generic formulation of Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%,and the current study is designed to evaluate the safety and efficacy of this formulation to determine if it is bioequivalent to Acanya.

Enrollment: 708 patients

Sex: All

Ages: 12 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Healthy male or non pregnant female
• ≥ 12 and ≤ 40 years
• Diagnosis of acne vulgaris (acne)
• >18 years and provide written informed consent
• Ages 12 to 17 and provide written assent and written informed consent from patient's legal representative
• Must sign a HIPAA authorization
• Minimum ≥ 25 non-inflammatory lesions
• ≥ 20 inflammatory lesions
• ≤ 2 nodulocystic lesions on the face
• Acne of severity grade 2, 3, or 4 -Investigator's Global Assessment (IGA)
• Refrain from all other topical acne medications or antibiotics during the 12-week treatment period except Investigational Product
• All Female patients with a negative urine pregnancy test who use birth control from the study start to 30 days after the last administration of study drug
• All male patients who use birth control with their partners, from the study start to 30 days after the last administration of study drug. Abstinence is acceptable. Female partners should use birth control
• Must be willing and able to understand and comply with the protocol requirements and required study visits
• In good health
• Free from any clinically significant disease
• Must have used the same brands/types of make-up for a minimum period of 14 days prior to study entry and must agree to use the same make-up, brand/type and maintain the same frequency of use throughout the study

Exclusion criteria

• Female patients who are pregnant, nursing or planning to become pregnant during study
• History or presence of Crohn's disease, ulcerative colitis, regional enteritis, or antibiotic-associated colitis
• Hypersensitivity or allergy to benzoyl peroxide, clindamycin and/or any of the study medication ingredients
• Presence of any skin condition that would interfere with the diagnosis or assessment
• Excessive facial hair
• Wax epilation of the face within 14 days prior
• Used oral retinoids or therapeutic vitamin A supplements of >10,000 units/day (multivitamins are allowed) within 6 months prior to or during the study
• Estrogens or oral contraceptives for <3 months prior to baseline; Use of such therapy must remain constant throughout the study
• Cryodestruction, chemodestruction, dermabrasion, photodynamic therapy, acne surgery, intralesional steroids, X-ray therapy procedures performed on the face within 1 month prior to or during the study
• Any systemic (steroids, antibiotics treatment for acne, anti-inflammatory agents) treatments within 1 month prior to baseline or during the study
• Any (topical steroids, topical retinoids, α-hydroxy/glycolic acid, benzoyl peroxide, topical anti-inflammatory agents, topical antibiotics) treatments within 2 weeks prior to baseline or during the study:
• Intend to use Spironolactone
• Intend to use tanning booths, sunbathing, or excessive exposure to the sun
• Radiation therapy and/or anti-neoplastic agents within 90 days prior to baseline
• Unstable clinically significant medical disorders or life-threatening diseases
• On-going malignancies requiring systemic treatment
• Any malignancy of the facial area skin
• Engage in activities that involve excessive or prolonged exposure to sunlight or weather extremes
• Consume excessive amounts of alcohol or use drugs of abuse
• Participation in an investigational drug study within 30 days prior
• Are participating in non-treatment studies such as observational studies or registry studies can be considered for inclusion
• Previously enrolled in this study
• Laser therapy, electrodessication and phototherapy to the facial area within 180 days prior to study entry
• Cosmetic procedures which may affect the efficacy and safety profile of the study drug within 14 days prior to study entry
• Currently have or have recently had bacterial folliculitis on the face

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

708 participants in 3 patient groups, including a placebo group

Acanya

Active Comparator group

Description:

Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% gel (Valeant Pharmaceuticals, North America)

Treatment:

Drug: Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%

Clindamycin Phosphate / Benzoyl Peroxide

Experimental group

Description:

Clindamycin Phosphate / Benzoyl Peroxide Gel, 1.2%/2.5%

Treatment:

Drug: Clindamycin Phosphate / Benzoyl Peroxide Gel

Vehicle Gel

Placebo Comparator group

Description:

Placebo (Vehicle Gel)of the test product (Watson Laboratories, Inc.)

Treatment:

Drug: Placebo (Vehicle Gel)